KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.
Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.
Sutro Biopharma and Celgene modified their 2014 immuno-oncology collaboration revolving around four programs that are in preclinical development.
Two pharma giants are combining forces to take on multiple cancers in a deal worth up to $8.5 billion.
Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.
Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Genentech is returning the rights to NewLink Genetics’ IDO inhibitor GDC-0919 (navoximod). However, the overall research collaboration the two companies have to identify next-generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors will continue.
Novartis and IBM Watson Health will explore ways to use patient data and advanced analysis to glean insights on the likely outcomes of breast cancer treatments.
J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.